Could a simple scan replace biopsies for key cancer marker?
NCT ID NCT06754345
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new radioactive tracer called 68Ga-NK224 that lights up PD-L1, a protein on cancer cells, during a PET/CT scan. Researchers want to see if the scan can accurately measure PD-L1 levels compared to standard tissue biopsy. One hundred adults with various cancers will be scanned, and the results will be compared to their biopsy reports. If it works, this could offer a less invasive way to guide immunotherapy decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-NK224 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging method could help doctors see PD-L1 levels in tumors without needing a biopsy, guiding better cancer treatment decisions.
What could go wrong
This is an early imaging study with 100 participants. It tests accuracy against biopsy results, so it may not change practice if the scan doesn't match well. No direct treatment benefit for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••